Syneos Health, Inc. (NASDAQ:SYNH) Shares Sold by Amalgamated Bank

Amalgamated Bank decreased its position in shares of Syneos Health, Inc. (NASDAQ:SYNHGet Rating) by 2.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 72,446 shares of the company’s stock after selling 1,932 shares during the quarter. Amalgamated Bank’s holdings in Syneos Health were worth $5,865,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of SYNH. BlackRock Inc. lifted its holdings in shares of Syneos Health by 16.3% during the first quarter. BlackRock Inc. now owns 11,527,780 shares of the company’s stock worth $933,174,000 after purchasing an additional 1,617,330 shares during the period. Silvercrest Asset Management Group LLC lifted its holdings in shares of Syneos Health by 490.6% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 1,427,767 shares of the company’s stock worth $145,924,000 after purchasing an additional 1,186,001 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of Syneos Health by 576.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,343,624 shares of the company’s stock worth $137,963,000 after purchasing an additional 1,144,983 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Syneos Health by 33.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 2,868,800 shares of the company’s stock worth $232,229,000 after purchasing an additional 723,812 shares during the period. Finally, Cooke & Bieler LP lifted its holdings in shares of Syneos Health by 39.1% during the first quarter. Cooke & Bieler LP now owns 2,359,503 shares of the company’s stock worth $191,002,000 after purchasing an additional 663,152 shares during the period. Institutional investors and hedge funds own 94.80% of the company’s stock.

Insiders Place Their Bets

In other Syneos Health news, General Counsel Jonathan Olefson sold 2,215 shares of the business’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $75.00, for a total transaction of $166,125.00. Following the transaction, the general counsel now owns 25,292 shares of the company’s stock, valued at $1,896,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Syneos Health news, General Counsel Jonathan Olefson sold 2,215 shares of the business’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $75.00, for a total transaction of $166,125.00. Following the transaction, the general counsel now owns 25,292 shares of the company’s stock, valued at $1,896,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Lee Brooks sold 1,002 shares of the company’s stock in a transaction on Tuesday, July 19th. The shares were sold at an average price of $74.00, for a total value of $74,148.00. Following the completion of the transaction, the chief operating officer now directly owns 49,556 shares in the company, valued at approximately $3,667,144. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,203 shares of company stock valued at $1,631,443. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

SYNH has been the subject of a number of analyst reports. William Blair downgraded Syneos Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 3rd. Mizuho decreased their price target on Syneos Health from $94.00 to $87.00 and set a “buy” rating for the company in a report on Wednesday, August 3rd. UBS Group initiated coverage on Syneos Health in a report on Wednesday, September 7th. They issued a “neutral” rating and a $68.00 price target for the company. Barclays decreased their price target on Syneos Health from $80.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, September 12th. Finally, Citigroup decreased their price target on Syneos Health from $80.00 to $70.00 in a report on Wednesday, August 3rd. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Syneos Health has an average rating of “Hold” and a consensus price target of $81.10.

Syneos Health Stock Down 1.9 %

Shares of SYNH opened at $51.51 on Monday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.10 and a current ratio of 1.10. Syneos Health, Inc. has a one year low of $50.74 and a one year high of $104.18. The stock has a market capitalization of $5.29 billion, a price-to-earnings ratio of 19.36 and a beta of 1.74. The stock has a 50 day moving average price of $66.90 and a 200 day moving average price of $71.76.

Syneos Health (NASDAQ:SYNHGet Rating) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.08 by $0.05. The firm had revenue of $1.36 billion during the quarter, compared to analysts’ expectations of $1.39 billion. Syneos Health had a return on equity of 14.04% and a net margin of 5.13%. The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.86 earnings per share. Equities research analysts forecast that Syneos Health, Inc. will post 4.54 earnings per share for the current fiscal year.

Syneos Health Company Profile

(Get Rating)

Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.

Recommended Stories

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health, Inc. (NASDAQ:SYNHGet Rating).

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.